Deliver efficacy readout of the adult RSV vaccine Phase 3 study
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 3 Jan 2023
- Due
- 31 Dec 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The study has been designed to provide an efficacy readout expected in the 2023 winter season.”
What we found
Evidence strength A What the grades mean
The company announced in January 2023 that the adult RSV Phase 3 trial met its primary efficacy endpoints, before the 2023 year-end deadline.
-
A Moderna 10-K filed 2024-02-23
“In January 2023, we announced that mRNA-1345 had met primary efficacy endpoints in the pivotal Phase 3 trial in older adults, ages 60 and older.” ✓ confirmed on the page
-
A Moderna 10-K filed 2024-02-23
“mRNA-1345 demonstrated vaccine efficacy (VE) of 83.7% (95.88% CI: 66.1%, 92.2%; p<0.0001) against RSV-associated lower respiratory tract disease (RSV-LRTD) as defined by two or more symptoms.” ✓ confirmed on the page
Market reaction: the shares moved -3.1% against the S&P 500 over the three sessions around the disclosure (22 Feb 2024 to 27 Feb 2024). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Deliver
- Deliverable
- Efficacy readout of RSV vaccine Phase 3 study in adults over 60
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Moderna? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-MRNA-006195 · Corrections policy